Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 60.2
Key Takeaways
Risk factor
Weak & very vulnerable to price shocks
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
ACRO Biomedical Co., Ltd. develops and produces biomaterial medical devices for human tissue engineering and regenerative medicine. The company was founded on June 26, 2014 and is headquartered in Kaoshiung, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only
Buy
Sell